Ovarian aging and systemic health: Mechanisms and emerging intervention strategies.
Key claim: Ovarian aging may drive systemic aging via cellular defects, SASP-related inflammaging, and estrogen decline, and ovary-targeted interventions such as senolytics may help preserve fertility and extend female healthspan.
Abstract
Ovarian aging may contribute to systemic aging via the ovarian-systemic axis. This review outlines intrinsic ovarian cellular defects such as genomic instability, epigenetic shifts, and mitochondrial and proteostasis damage, which may trigger senescence-associated secretory phenotype (SASP)-related inflammaging, fibrosis, and distal pro-aging signals. Ovarian-derived endocrine disruption, especially estrogen decline, broadly affects bodily physiology. We summarize emerging multimodal interventions, including senolytics, metabolic reprogramming, regenerative medicine, and systemic approaches, and we discuss their dual potential to preserve fertility and intercept ovarian contributions to systemic aging. Ovarian aging is possibly associated with female age-related multimorbidity. Ovary-targeted prevention may extend healthspan, as assessed by combined reproductive and systemic clinical evaluations.
Why this matters
This review consolidates a growing frame in which the ovary is not just a downstream target of aging but a pre-menopausal upstream driver of it in females, via granulosa/oocyte cellular defects, local SASP-driven inflammaging, and estrogen withdrawal that then propagates systemically. It knits together several previously separate mechanism pages (senescence, inflammaging, mitochondrial dysfunction, epigenetic drift, menopause) around a single sex-specific tissue axis, and formalizes the pitch for ovary-targeted senolytics and regenerative interventions — a therapeutic narrative that currently runs well ahead of any human outcome data on female healthspan.